A Study on the Efficacy and Safety of IPyC for HER2+ MBC

Fujian Medical University301 enrolled

Overview

Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity. Efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR).

Study Type

OBSERVATIONAL

Enrollment

301

Conditions

Breast Cancer

Interventions

Inetetamab and Pyrotinib Combined with ChemotherapyDRUG

Inetetamab and Pyrotinib Combined with Chemotherapy

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients who underwent a biopsy of the metastatic site and were confirmed as having MBC * patients who received inetetamab + pyrotinib + chemotherapy as metastasis therapy. Exclusion Criteria: * male patients or individuals with prior malignancy * patients with prior or current enrollment in interventional clinical trials for MBC * patients who received less than 2 cycles of treatment (6 weeks of inetetamab or 8 weeks of pyrotinib) * patients who were lost to follow-up during the therapeutic process

Locations (1)

Fujian Cancer Hospital

Fuzhou, China

Outcomes

Primary Outcomes

progression-free survival (PFS)

Time frame: 2 years

Secondary Outcomes

objective response rate (ORR)

Time frame: 2 years

clinical benefit rate (CBR)

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.